Hone builds hybrid in-home care

This deal shows Hone moving from a telehealth prescribing business into a care delivery model that can own more of the patient workflow. Testosterone treatment is not a one time prescription. It requires repeat lab work, dose changes, and ongoing monitoring. By adding ivee’s in home blood draws and other home services, Hone can reduce drop off between diagnosis, follow up testing, and treatment changes, while making the experience feel closer to concierge care than a website pharmacy.

• Hone’s core product already depended on recurring consultations, blood work, and medication adjustments, with revenue anchored by a $129 per month consult subscription plus paid add ons like testosterone and anastrozole. In home phlebotomy fits directly into that existing loop, it is not a side service.
  2 sacra 3 sacra
• The acquisition also gives Hone physical coverage in 20 major metro areas and adds services beyond lab collection, including IV therapy. That matters because many D2C telehealth companies stop at the prescription, while Hone can now put a clinician or technician into the home for higher touch care.
  1 businesswire 3 sacra
• There is a broader pattern in consumer health of adding offline infrastructure to strengthen retention and raise spend per customer. Function Health uses Quest’s draw network for testing, while Noom and Hims layer coaching or prescribing on top of software. Hone is taking the more operationally heavy path of controlling the home visit itself.
  4 sacra 5 sacra 2 sacra

The next step is a fuller hybrid clinic model where Hone uses telehealth to acquire patients, then uses labs, home visits, and new longevity treatments to keep them engaged for years. That pushes the business toward higher lifetime value and makes it harder for lighter weight telehealth competitors to match the experience with software alone.